Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.61 |
| ▸ | ESRRA | P11474 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.48 |
| ▸ | PPARA | Q07869 | 4/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3240996 | 0.94 | PPARG (0.64) | PPARGESRRAFFAR1PPARAEPHX2 | |
| SCHEMBL3246683 | 0.90 | PPARG (0.58) | PPARGESRRAFFAR1PPARA | |
| SCHEMBL3245510 | 0.89 | PPARG (0.68) | PPARGESRRAFFAR1PPARA | |
| SCHEMBL3242598 | 0.87 | PPARG (0.62) | PPARGESRRAFFAR1PPARA | |
| SCHEMBL3246419 | 0.87 | PPARG (0.65) | PPARGESRRAFFAR1PPARA | |
| SCHEMBL3250235 | 0.87 | PPARG (0.67) | PPARGESRRAFFAR1PPARA | |
| Hydrochloric Acid SCHEMBL3244934 | 0.87 | PPARG (0.61) | PPARGESRRAFFAR1PPARA | |
| SCHEMBL3245228 | 0.86 | PPARG (0.65) | PPARGESRRAFFAR1PPARA | |
| SCHEMBL3245993 | 0.85 | PPARG (0.63) | PPARGESRRAFFAR1PPARA | |
| SCHEMBL3251055 | 0.85 | PPARG (0.60) | PPARGESRRAFFAR1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | PPARG 929/4885ESRRA 961/4885FFAR1 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.